Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance

Kuo-Hsing Chen1,4,6, Chang-Tsu Yuan2, Li-Hui Tseng3, Chia-Tung Shun2,5,7 and Kun-Huei Yeh1,6*

Abstract

Background: Anti-programmed death-1 therapy has poor efficacy in mismatch repair-proficient (pMMR) colorectal cancers; however, its efficacy in pMMR gastric cancers remains undetermined. Here, we report the case of a patient with pMMR and microsatellite-stable gastric cancer who exhibited a partial response to salvage anti-programmed death-1 therapy with pembrolizumab.

Case presentation: Initially, the patient underwent subtotal gastrectomy 4 years ago for early-stage gastric cancer (pT1bN2M0, stage IIA). Immunohistochemical analysis of the tumor revealed strongly positive for HER2/neu. He had received trastuzumab plus pertuzumab, cisplatin, and capecitabine for recurrent tumors since September 2014 for 15 cycles. Disease progression of gastric cancer was found in August 2015. Since September 2015, the patient has received pembrolizumab monotherapy (200 mg as a fixed dose, every 3 weeks) for 3 months and the repeat computed tomography demonstrated a confirmed partial response. The plasma carcinoembryonic antigen also decreased dramatically. Both immunohistochemistry and a polymerase chain reaction-based method revealed that the patient had pMMR gastric cancer.

Conclusions: This case report provides the first report that mismatch repair-proficient and microsatellite-stable gastric cancers can respond well to anti-PD-1 monotherapy and indicates both markers may not sufficiently be predictive of anti-PD-1 therapy resistance in gastric cancer.

Keywords: Gastric cancer, Immunotherapy, Anti-programmed death-1 antibody, Mismatch repair deficiency, Mismatch repair proficiency, Microsatellite stability

Background

Immune checkpoint blockade therapies such as those using anti-cytotoxic T lymphocyte-associated protein 4 antibodies and those blocking programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have exhibited promising efficacy in several types of cancer [1–7]. Moreover, the heterogeneous response to immune checkpoint blockade therapy observed in patients in these studies has raised the importance of identifying predictive biomarkers. Mutation or hypermethylation in mismatch repair genes (MLH1, MSH2, MSH6, or PMS2) leads to deficient mismatch repair (dMMR) and causes accumulation errors in DNA sequences, thus increasing the risk of colorectal cancer (CRC) and other epithelial cancers [8]. Recently, Le et al. reported that patients with mismatch repair-deficient CRC and those with mismatch repair-deficient noncolorectal cancer exhibited higher response rates to PD-1 blockade monotherapy (pembrolizumab). In addition, they suggested that hypermutated tumor-associated neoantigens from dMMR are the primary factors affecting the response to anti-PD-1 therapy; previous studies have observed that this therapy stimulated the endogenous immune response [3, 9, 10]. However, Le et al. also reported that none of 18 patients
with mismatch repair-proficient (pMMR) CRC responded to pembrolizumab, an anti-PD-1 antibody. The efficacy of PD-1 blockade therapy in pMMR noncolorectal cancers and a biomarker for PD-1 blockade remain unknown. Here, we report the case of a 64-year-old man with pMMR and microsatellite-stable (MSS) gastric cancer who exhibited a partial response to salvage pembrolizumab monotherapy.

Case presentation
A 64-year-old man experienced epigastralgia with tarry stool in late 2011. Esophagogastroduodenoscopy revealed a circular ulcer in the prepyloric area. Biopsy was performed, and the pathology of the specimen revealed gastric adenocarcinoma. On the basis of computed tomography (CT), the gastric cancer was clinically staged as cT3N0M0, stage IIA. He underwent radical subtotal gastrectomy, Billroth II anastomosis, D2 dissection, and cholecystectomy on December 28, 2011. The pathology of the specimen revealed a well-differentiated adenocarcinoma, and Helicobacter pylori infection was not observed (Fig. 1a). Immunohistochemically, tumor cells were strongly positive (3+, according to the proposal by Hofmann et al. [11]) for HER2/neu immunostain (clone 4B5, 1:2 dilution; Fig 1b). The pathological staging of the gastric cancer was pT1bN2M0, stage IIA. After surgery, he was followed up regularly at our hospital without adjuvant treatment.

Two years later, CT and positron emission tomography revealed tumor recurrence in the left lower paratracheal lymph nodes. The patient was then enrolled in a clinical trial and received 15 cycles of pertuzumab (840 mg on D1, every 3 weeks) in combination with trastuzumab (562 mg on D1, every 3 weeks) and chemotherapy (80 mg/m² cisplatin on D1 and 1000 mg/m² capecitabine twice a day on D1−D14, every 3 weeks). He was dropped from the study in August 2015 because the tumors (peritoneal seeding and paraaortic lymph nodes) progressed and his plasma carcinoembryonic antigen (CEA) level increased from 4.78 to 348 ng/mL. To investigate the association of the tumor factors with the efficacy of PD-1 blockade as well as to confirm whether he had pMMR gastric cancer, we used both immunohistochemistry (IHC) and a polymerase chain reaction-based method (Fig. 3) [12]. In addition, we performed IHC analyses of previous specimens from gastrectomy, which revealed few tumor-infiltrating lymphocytes (TILs) in tumors and invasive fronts, as demonstrated by the presence of CD3 (polyclonal, 1:100), CD4 (clone MT310, 1:50), and CD8 (clone DK-25, 1:200; Fig. 4a–c). Epstein–Barr virus (EBV)-encoded small RNA (EBER) in situ hybridization revealed absence of EBV in the tumor cells (Fig. 4d). The tumor cells were also negative for PD-L1 (B7H1, Abcam, clone ab58810, 1:400; Fig. 5) [13]. Moreover, no polymerase epsilon (POLE) mutation was found by means of Sanger sequencing of exon 9. As of January 2016, the patient was still continuing the pembrolizumab monotherapy with excellent performance status and quality of life.

Discussion
Evaluations of the efficacy of PD-1 blockade in advanced esophagogastric junction (EGJ) and gastric adenocarcinoma are still preliminary, and an accurate predictive biomarker remains to be determined. Bang et al. reported that the overall response rate of pembrolizumab (by central review) in advanced PD-L1-positive gastric cancer was 22.2 % [95 % confidence interval, 10.1−39.2] in a phase 1 study (KEYNOTE-012 study, gastric cancer cohort) [14]. Of the 162 patients screened, 65 were positive for PD-L1.

Fig. 1Histopathology of the gastric cancer and its HER2 immunohistochemistry. Microscopic observation revealed a well-differentiated adenocarcinoma with frequent luminal formation and evident nuclear atypia infiltration within a mild desmoplastic stroma; H & E stain (a). In the metastasized lymph node, the tumor cells were strongly positive for the HER2/neu immunostain (brown color) (b); original magnification ×100
The PD-L1 expression was detected through a prototype IHC assay by using the 223C antibody, and the tumors were determined positive for PD-L1 when PD-L1 staining was observed in the stroma or ≥ 1% of tumor nest cells. However, PD-L1 expression is not yet a validated predictive biomarker for PD-1 blockade in gastric cancer. Moreover, dMMR has been identified in gastric cancer in several studies with the incidence ranging from 9 to 22% [15–19]. In a study conducted using the Cancer Genome Atlas (TCGA), 22% of the tumors belonged to the microsatellite instability (MSI) subtype, with the features of hypermutation and MLH1 silencing. Although pMMR has been shown to predict poor efficacy of PD-1 blockade in CRC, the association of pMMR and PD-1 blockade in EGJ and gastric adenocarcinoma remains unknown. This case report provides the first report that pMMR and MSS gastric cancers can respond well to anti-PD-1 monotherapy. However, larger studies are warranted to explore the association between mismatch repair status and the efficacy of anti-PD-1 therapy in advanced gastric cancer.

The hypothesis that neoantigens from hypermutated tumors may enhance the response of immune checkpoint therapy was supported by clinical correlative studies on melanoma and non-small-cell lung cancer [3, 20, 21]. In addition to dMMR, inactivating POLE mutation, found in CRC, endometrial cancer, and gastric cancer, can result in an extremely high mutation burden [15, 22, 23]. Howitt et al. demonstrated that increased TILs in the tumor microenvironment in POLE-mutated endometrial cancers make these tumors satisfactory candidates for immune checkpoint therapy [23]. We cannot completely exclude the possibility that our patient had a POLE-mutated tumor; however, the incidence of POLE mutation in gastric cancer is very low (0.47%) and TILs in the tumor microenvironment were scant in our patient [15].
PD-L1 has been reported to be overexpressed in EBV-associated malignancies, such as EBV-associated lymphoproliferative diseases, nasopharyngeal carcinoma, and HHV8-associated primary effusion lymphoma [24, 25]. The mechanisms underlying increased PD-L1 expression in Hodgkin lymphoma include genetic amplification of CD274 (encoding PD-L1) and constitutive AP1 signaling. The TCGA study also revealed that the amplification of CD274 and PDCD1LG2 (also encoding PD-L1 and PD-L2) was enhanced in the EBV-positive gastric cancer subgroup [15]. Thus, these cancers are attractive targets for immune checkpoint therapy. In our patient, EBER in situ hybridization revealed absence of EBV in the tumor cells, and it is unlikely that the efficacy of anti-PD-1 therapy is affected by EBV-related CD274 and PDCD1LG2 amplification.

**Conclusions**

In conclusion, we report the case of a patient with pMMR and MSS gastric cancer who exhibited a confirmed objective response to PD-1 blockade, pembrolizumab monotherapy. Our case report indicates that mismatch repair proficiency and microsatellite stability may not be predictive to resistance of anti-PD-1 therapy, and factors other than dMMR and EBV infection may contribute to the response to anti-PD-1 therapy.

**Consent for publication**

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal. The institutional review board of National Taiwan University Hospital approved the study.

**Abbreviations**

CRC: colorectal cancer; CT: computed tomography; dMMR: deficient mismatch repair; EBV: Epstein–Barr virus; EBER: Epstein–Barr virus-encoded small RNA; EGJ: esophagogastric junction; IHC: immunohistochemistry; PD-1: programmed death-1; PD-L1: programmed death ligand-1; pMMR: mismatch repair-proficient; MSI: microsatellite instability; MSS: microsatellite stable; POLE: polymerase epsilon; TCGA: the Cancer Genome Atlas; TILs: tumor-infiltrating lymphocytes.
Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Dr. Yeh had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. KH Yeh and KH Chen did the study concept, design, and drafting of the manuscript. KH Yeh, KH Chen, CT Shun, and CT Yuan did the acquisition, analysis, and interpretation of data. LH Tseng did the genetic testing of microsatellite instability and POLE mutations. All authors read and approved the final manuscript.

Funding
This study was supported by a grant from Center of Excellence for Cancer Research (2014 to 2017), National Taiwan University Hospital (MOH91W105-TDU-B-211-134004).

Author details
1Department of Oncology, National Taiwan University Hospital, 7, Chun-Shan S Rd, Taipei 10002, Taiwan. 1Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan. 1Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan. 1National Taiwan University Cancer Center, Taipei, Taiwan. 1Department of Forensic Medicine, National Taiwan University, Taipei, Taiwan. 1Graduate Institute of Oncology, National Taiwan University, Taipei, Taiwan. 1Forensic Medicine, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Received: 18 February 2016 Accepted: 15 March 2016

Published online: 24 March 2016

References
1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvalj RD, Sosman JA, Atkins MB. Safety, activity, and immune correlates of anti-CD1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.
3. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheur D. POI-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2012;366(26):2509–20.
4. Ansell SM, Leschik AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattrey DJ, Freeman GJ. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2013;369(24):234–5.
5. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Puzanov I, Vokes EE, Holgado E. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.
6. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutnikov P. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
7. Brahmer JR, Tykodi SS, Chow LQ, Hwu JW, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Oudassi K. Safety and activity of anti-POI-1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.
8. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348(10):919–32.
9. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenleieder EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS. The vigorous immune microenvironment of microsatellite unstable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer discovery. 2015;5(1):43–51.
10. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 1994;145(1):1148–56.
11. Hofmann M, Stoss D, Gaisser T, Komlatsky H, Himmler P, Just A, Hauke M, Henkel T, Ruschoff J, Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polymorys. Journal of clinical pathology. 2008;61(1):89–94.
12. Tsai JT, Lin YL, Cheng YC, Chen CC, Lin LI, Tseng LH, Cheng ML, Liao JY, Jeng YM. Aberrant expression of annexin A10 is closely related to gastric phenotype in seriated pathway to colorectal carcinoma. Modern pathology. 2015;28(2):268–78.
13. Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M, Meng YL, Yang AG, Wen WH. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS One. 2013;8(10):e76012.
14. Bang YJ, Shankaran V, Geva R, Yang AG, Wen WH. Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. J Clin Oncol. 2015;33(suppl abstr 4001).
15. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.
16. Kim KJ, Jung HY, Oh MH, Cho H, Lee JH, Lee HU, Jang SH, Lee MS. Loss of ARD1 expression in gastric cancer: correlation with mismatch repair deficiency and clinicopathologic features. Journal of gastric cancer. 2015;15(2):201–4.
17. van Grieken NC, Aoyama T, Chambers PA, Bottomley D, Ward LC, Iham I, Buffart TE, Das K, Lim T, Pang B. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. Br J Cancer. 2013;108(7):1495–501.
18. Wu MS, Lee CW, Shun CT, Wang HL, Lee WU, Chang MC, Sheu JC, Lin JT. Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer. 2000;27(4):403–11.
19. Simpson AJ, Caballero OL, Pena SD. Microsatellite instability as a tool for the classification of gastric cancer. Trends Mol Med. 2001;7(2):76–80.
20. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Pong W, Ho TS. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–99.
21. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JI, Lee W, Yuan J, Pong W, Ho TS. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, NY). 2015;348(6230):124–8.
22. Palles C, Cazier JB, Howarth KM, Domingo E, Broderick P, Kemp Z, Spain SL, Guirado E, Salguero I. Germline mutations affecting the mismatch repair genes and microsatellite-unstable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA oncology. 2015;10(19):1319–23.
23. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clinical cancer research. 2013;19(13):3462–73.
24. Green MR, Rodig S, Juzcszynki P, Ouyang J, Sinha P, ODennell E, Neuberg D, Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clinical cancer research. 2012;18(6):1611–8.